Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 33K
6: R1 Document and Entity Information Document HTML 46K
8: XML IDEA XML File -- Filing Summary XML 11K
5: XML XBRL Instance -- nvcr-20210609_htm XML 22K
7: EXCEL IDEA Workbook of Financial Reports XLSX 6K
3: EX-101.LAB XBRL Labels -- nvcr-20210609_lab XML 67K
4: EX-101.PRE XBRL Presentations -- nvcr-20210609_pre XML 33K
2: EX-101.SCH XBRL Schema -- nvcr-20210609 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
10: ZIP XBRL Zipped Folder -- 0001645113-21-000073-xbrl Zip 12K
(State
or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
iNo. 4 The Forum, Grenville Street
iSt.
Helier
iJersey
iJE2 4UF
(Address of Principal Executive Offices)
(Zip
Code)
+i44 (0) 15i3475 6700
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iOrdinary
Shares, no par value
iNVCR
iThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Election of Directors
On June 9, 2021, NovoCure Limited (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). The
Company’s shareholders elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Kinyip Gabriel Leung, Martin Madden, Sherilyn McCoy, Timothy Scannell and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2022. The election of these directors was not pursuant to any arrangement or understanding between any of them and any third party. As of the date of this report, none of these directors, nor any of their immediate family members, is a party, either directly or indirectly, to any transaction that would be required to be reported pursuant to Item 404(a) of Regulation S-K. These directors will be compensated consistent with the compensation programs for non-employee directors.
Item 5.07. Submission of Matters to a Vote of Security Holders
At
the Annual Meeting, proxies and in-person shareholders representing 90,677,622 shares of the Company’s ordinary shares, or approximately 87.87% of the total shares entitled to vote, were present in person or by proxy and voted on the following proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 27, 2021.
1. Election of Directors. The five nominees for election to the Company’s Board of Directors were elected
as directors to hold office until the Company’s 2021 Annual Meeting of Shareholders or until their successors are duly elected and qualified or until their offices are vacated, based upon the following votes:
For
Against
Abstain
Broker non-votes
Asaf
Danziger
82,920,076
182,595
37,355
7,537,596
William Doyle
81,879,493
1,223,165
37,368
7,537,596
Jeryl Hilleman
82,913,275
180,827
45,924
7,537,596
David Hung
82,699,463
395,053
45,510
7,537,596
Kinyip
Gabriel Leung
82,789,815
312,570
37,641
7,537,596
Martin Madden
82,909,463
184,070
46,493
7,537,596
Sherilyn McCoy
67,894,584
15,200,551
44,891
7,537,596
Timothy Scannell
81,722,694
1,372,005
45,327
7,537,596
William
Vernon
80,118,299
2,975,455
46,272
7,537,596
2. Ratification of Independent Registered Public Accounting Firm. The proposal to approve and ratify the appointment, by the audit committee of the Company’s Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the
Company for the fiscal year ending December 31, 2021 was approved based upon the following votes:
For
Against
Abstain
89,961,931
667,878
47,813
3.
Approval of a non-binding advisory vote to approve executive compensation. The proposal to approve executive compensation on a non-binding advisory basis was approved based upon the following votes:
For
Against
Abstain
Broker non-votes
63,522,659
19,533,075
84,292
7,537,596
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
